• The Hurdles of Insuring Patients with Nano-rare Mutations with Alan Lotvin, M.D.

  • May 29 2024
  • Length: 51 mins
  • Podcast

The Hurdles of Insuring Patients with Nano-rare Mutations with Alan Lotvin, M.D.

Listen for free

View show details

  • Summary

  • What's preventing insurers from covering the specialized care of patients with nano-rare mutations, thereby expanding access to available treatment options? Is it the population size, cost, or perceived risk? Given that the initial discovery of nano-rare mutations is relatively recent, paving the way for this population requires a nuanced approach to overcome various obstacles. Alan Lotvin, M.D., CEO and co-founder of Sequel Med Tech, and former president of CVS Caremark, conceptualizes these hurdles.

    Show more Show less
activate_WEBCRO358_DT_T2
Physical Illness & Disease Hygiene & Healthy Living Biological Sciences
Show more Show less

What listeners say about The Hurdles of Insuring Patients with Nano-rare Mutations with Alan Lotvin, M.D.

Average customer ratings

Reviews - Please select the tabs below to change the source of reviews.

Audible.com reviews

Amazon reviews
No Reviews are Available